{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+III+Skin+Cancer&page=2", "query": { "condition": "Stage III Skin Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+III+Skin+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T17:23:03.589Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04315701", "title": "A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Skin Squamous Cell Carcinoma", "Resectable Skin Squamous Cell Carcinoma", "Stage I Skin Cancer", "Stage II Skin Cancer", "Stage III Skin Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2020-06-17", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-25T17:23:03.589Z", "location_count": 5, "location_summary": "Los Angeles, California • Newport Beach, California • Chicago, Illinois + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04315701" }, { "nct_id": "NCT04995094", "title": "Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pathologic Stage III Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Imprime PGG", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "HiberCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-08-15", "completion_date": "2023-05-18", "has_results": false, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-06-25T17:23:03.589Z", "location_count": 4, "location_summary": "La Jolla, California • Whittier, California • New York, New York + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04995094" }, { "nct_id": "NCT00524277", "title": "Vaccine Therapy in Treating Patients With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GP2 peptide + GM-CSF vaccine", "type": "BIOLOGICAL" }, { "name": "GM-CSF (sargramostim)", "type": "BIOLOGICAL" }, { "name": "AE37 + GM-CSF vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "San Antonio Military Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 456, "start_date": "2007-01", "completion_date": "2017-03-31", "has_results": false, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-06-25T17:23:03.589Z", "location_count": 11, "location_summary": "Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 7 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524277" }, { "nct_id": "NCT01875653", "title": "Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage IV Melanoma", "Stage III Melanoma" ], "interventions": [ { "name": "Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)", "type": "BIOLOGICAL" }, { "name": "Autologous PBMCs in GM-CSF (MC)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lisata Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2014-10", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2019-05-10", "last_synced_at": "2026-06-25T17:23:03.589Z", "location_count": 18, "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01875653" }, { "nct_id": "NCT00079222", "title": "Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "itraconazole", "type": "DRUG" }, { "name": "voriconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": null, "start_date": "2003-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-06-25T17:23:03.589Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079222" }, { "nct_id": "NCT02370277", "title": "Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ductal Breast Carcinoma In Situ", "Invasive Breast Carcinoma", "Stage I Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer" ], "interventions": [ { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 36, "start_date": "2014-12-16", "completion_date": "2018-08-22", "has_results": false, "last_update_posted_date": "2019-06-18", "last_synced_at": "2026-06-25T17:23:03.589Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02370277" }, { "nct_id": "NCT05764395", "title": "Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma", "Refractory Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Rigosertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-05-09", "completion_date": "2029-05-01", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-06-25T17:23:03.589Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05764395" }, { "nct_id": "NCT05086731", "title": "Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Localized Breast Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Informational Intervention", "type": "OTHER" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2021-10-22", "completion_date": "2024-03-06", "has_results": false, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-06-25T17:23:03.589Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086731" }, { "nct_id": "NCT00014222", "title": "Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "epoetin alfa", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "NCIC Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "FEMALE", "summary": "Up to 60 Years · Female only" }, "enrollment_count": 2104, "start_date": "2000-12-04", "completion_date": "2014-03-17", "has_results": true, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-06-25T17:23:03.589Z", "location_count": 44, "location_summary": "Fort Smith, Arkansas • Little Rock, Arkansas • La Jolla, California + 39 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Greenwich", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014222" }, { "nct_id": "NCT00425672", "title": "ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "ONTAK", "type": "BIOLOGICAL" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "protein expression analysis", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "GENETIC" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2005-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2018-12-05", "last_synced_at": "2026-06-25T17:23:03.589Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00425672" } ] }